Y N Li1, F L Hu1, Y J Dai1, R Li1, X X Ma1, Y Du1, M Feng1, Y Jia1, C F Zhang2, L Zhu1, D P Ascherman3, Z G Li4. 1. Department of Rheumatology & Immunology, Peking University People's Hospital, Beijing, China. 2. Clinical Epidemiology & Biostatistics, Peking University People's Hospital, Beijing, China. 3. Department of Medicine, Division of Rheumatology, University of Miami Miller School of Medicine, USA DAscherman@med.miami.edu. 4. Department of Rheumatology & Immunology, Peking University People's Hospital, Beijing, China DAscherman@med.miami.edu.
Abstract
BACKGROUND: Previous work suggests that lipocalin 2 is involved in the pathogenesis of systemic lupus erythematosus (SLE) and that this novel antigen could serve as a high-quality renal biomarker of acute kidney injury in SLE. However, serum lipocalin 2 antibody levels remain unclear. We have therefore undertaken this study to assess the level of serum IgG antibody against lipocalin 2 in different disease states and to evaluate the diagnostic value of this potential biomarker in SLE. METHODS: Serum levels of anti-lipocalin IgG antibodies were measured by ELISA in 103 SLE patients, 93 rheumatoid arthritis (RA) patients, 29 primary Sjögren's syndrome (pSS) patients, 13 systemic sclerosis (SSc) patients, and 91 healthy controls. Diagnostic properties of anti-lipocalin IgG were determined by receiver-operating characteristic (ROC) curve analysis. RESULTS: The level of serum anti-lipocalin IgG in patients with SLE was significantly higher than in patients with RA, pSS, SSc, or healthy controls (p < 0.05), effectively distinguishing SLE from other conditions with high sensitivity and specificity (49.5% and 90.7%, respectively). In ROC curve analysis, the area under the curve (AUC) is 0.783, with a 95% confidence interval (CI) extending from 0.729 to 0.839. Anti-lipocalin antibodies were present in 48.1% of anti-Sm-negative SLE patients, and also occurred in SLE patients lacking anti-dsDNA (52%) or anti-nucleosome antibodies (46.3%) antibodies. Finally, SLE patients with positive anti-lipocalin IgG possessed higher levels of IgA and CRP than the negative group (p < 0.05), clearly demonstrating a positive correlation between anti-lipocalin IgG and these laboratory parameters. CONCLUSIONS: Anti-lipocalin 2 IgG is a promising biomarker for the diagnosis of SLE, particularly when obtained in conjunction with anti-Sm, anti-dsDNA, and anti-nucleosome antibody levels.
BACKGROUND: Previous work suggests that lipocalin 2 is involved in the pathogenesis of systemic lupus erythematosus (SLE) and that this novel antigen could serve as a high-quality renal biomarker of acute kidney injury in SLE. However, serum lipocalin 2 antibody levels remain unclear. We have therefore undertaken this study to assess the level of serum IgG antibody against lipocalin 2 in different disease states and to evaluate the diagnostic value of this potential biomarker in SLE. METHODS: Serum levels of anti-lipocalin IgG antibodies were measured by ELISA in 103 SLEpatients, 93 rheumatoid arthritis (RA) patients, 29 primary Sjögren's syndrome (pSS) patients, 13 systemic sclerosis (SSc) patients, and 91 healthy controls. Diagnostic properties of anti-lipocalin IgG were determined by receiver-operating characteristic (ROC) curve analysis. RESULTS: The level of serum anti-lipocalin IgG in patients with SLE was significantly higher than in patients with RA, pSS, SSc, or healthy controls (p < 0.05), effectively distinguishing SLE from other conditions with high sensitivity and specificity (49.5% and 90.7%, respectively). In ROC curve analysis, the area under the curve (AUC) is 0.783, with a 95% confidence interval (CI) extending from 0.729 to 0.839. Anti-lipocalin antibodies were present in 48.1% of anti-Sm-negative SLEpatients, and also occurred in SLEpatients lacking anti-dsDNA (52%) or anti-nucleosome antibodies (46.3%) antibodies. Finally, SLEpatients with positive anti-lipocalin IgG possessed higher levels of IgA and CRP than the negative group (p < 0.05), clearly demonstrating a positive correlation between anti-lipocalin IgG and these laboratory parameters. CONCLUSIONS: Anti-lipocalin 2 IgG is a promising biomarker for the diagnosis of SLE, particularly when obtained in conjunction with anti-Sm, anti-dsDNA, and anti-nucleosome antibody levels.
Authors: Elise V Mike; Hadijat M Makinde; Maria Gulinello; Kamala Vanarsa; Leal Herlitz; Gaurav Gadhvi; Deborah R Winter; Chandra Mohan; John G Hanly; C C Mok; Carla M Cuda; Chaim Putterman Journal: J Autoimmun Date: 2018-08-30 Impact factor: 7.094
Authors: Saifur Rahman; Divya Sagar; Richard N Hanna; Yaima L Lightfoot; Pragnesh Mistry; Carolyne K Smith; Zerai Manna; Sarfaraz Hasni; Richard M Siegel; Miguel A Sanjuan; Roland Kolbeck; Mariana J Kaplan; Kerry A Casey Journal: Ann Rheum Dis Date: 2019-04-30 Impact factor: 19.103
Authors: Sonja Hatz; Scott Spangler; Andrew Bender; Matthew Studham; Philipp Haselmayer; Alix M B Lacoste; Van C Willis; Richard L Martin; Harsha Gurulingappa; Ulrich Betz Journal: PLoS One Date: 2019-04-08 Impact factor: 3.240